No Detail Found!

Prediction of Kinetic Models on Dissolution Profile and in Vitro Quality Control Analysis on Several Brands of Ebastine (10mg) Available in Karachi, Pakistan

Author(s)
Hira Akhtar Department of Pharmaceutics, Nazeer Hussain University, Karachi Pakistan; Faculty of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutics, University of Karachi, Pakistan
Laiba Athar students of Nazeer Hussain University,Karachi,Pakistan
Areeba Akhtar students of Nazeer Hussain University,Karachi,Pakistan
Saba Fatima students of Nazeer Hussain University,Karachi,Pakistan
Reshma Alam students of Nazeer Hussain University,Karachi,Pakistan
Abstract
Purpose: This investigation focuses on conducting a comprehensive in vitro standard evaluation of 10 different Brands Ebastine tablets (10mg) available in Karachi, Pakistan. The basic findings of this study is to ensure that the selected Ebastine brands from Karachi, Pakistan meet the in vitro quality parameters as specified in United states Pharmacopeia. Methodology: The study involved application of Pharmacopeial and non Pharmacopeial tests on 10 different brands on Ebastine tablets Including weight variation, friability, disintegration, dissolution, assay and thickness, diameter, hardness. Model dependent and independent approaches were applied included First-order, Higuichi, Hixson Crowell and Well model and model dependent approaches the difference (f1) and similarity (f2) factors for were applied on multiple point dissolution data through Dissolution Data solver (DD- Solver) an add-in program in Excel. Result: The average weight variation of ten brands of Ebastine brands fell within the USP specification of ±7.5% deviation (193-212 mg). Hardness of Ebastine were found to be in the range of 4.38±0.1-4.98±0.5 kg which meets the standard value 4-10 kg. Thickness of Ebastine is 1.25±0.2-1.43±0.2mm and diameter was fond to be 3.02±0.2-5.59±0.4 mm. Disintegration time of all ten selected brands of Ebastine was below 15 minutes. Friability ranged from 0.80.91% within the standard limit, indicating tablets' sufficient mechanical strength. Several kinetic models were successfully applied using DD Solver an add in Program in Excel it was concluded on the basis of r2 0.9903 value all ten brands of Ebastine followed weibull model and f1 similarity and f2 dissimilarity values were found to be 3.59-10.96 & 50.44-71.56. Conclusion: The study successfully conducted Pharmacopeial and nonPharmacopeial tests on ten different brands Ebastine 10 mg brands accessible in Karachi, Pakistan, indicating conformity with USP specifications.
Publication Details
Page(s) 178-185
DOI DOI not available
Published Journal: RADS Journal of Pharmacy and Allied Health Sciences, Volume: 2, Issue: 4, Year: 2024

Request the full text from PASTIC

Keywords
ebastine, antihistamine, Pakistan, efficacy, In Vitro Testing, Pharmacokinetics
References
Mimmi SFH,Rahman S,Areefin P,Mostaid MS,Siddique MA .2024 .Comparative in-vitro evaluation of ebastine tablets (10 mg) available in bangladesh. , 23(1) : 70673-53.
Quodbach J,Kleinebudde PJPd .2015 .. A critical review on tablet disintegration, 10456 18(6) : 763-74.
Ubhe TS,Gedam P. .2020 .A brief overview on tablet and it's types. Journal of Advancement in Pharmacology, 1(1) : 21-31.
Dasari T,Kala SLJ,Nadendla RRJSAJP .2017 .In process quality control tests of solid dosage forms: a comprehensive review. , 10(8) : 334-45.
Osei-Yeboah F .2015 .Validation and applications of an expedited tablet friability method. , 02(1-2) : 146-55.
Al-Gousous J,Langguth PJJops J .2015 .Oral solid dosage form disintegration testing-The forgottentest. , 104(9) : 2664-75.
Markl D,Zeitler JAJPr D .2017 .A review of disintegration mechanisms and measurement techniques. , 34(5) : 890-917.
Sastre JJJIACI .2020 .Ebastine in the treatment of allergic rhinitis and urticaria: 30 years of clinical studies and real-world experience. , 10(3) : 156-68.
Moore J,Flanner J .1996 .HJPt. Mathematical comparison of dissolution profiles, 20(6) : 64-74.
Gupta A,Hunt RL,Khan MAJAJoH .2008 .Influence of tablet characteristics on weight variability and weight loss in split tablets. , 65(24) : 2326-8.
Koner JS,Rajabi-Siahboomi AR,Missaghi S,Kirby D,Perrie Y,Ahmed J .2019 .Conceptualisation, development, fabrication and in vivo validation of a novel disintegration tester for orally disintegrating tablets. , 9(1) : 12467.
Mimmi SFH,Rahman S,Areefin P,Mostaid MS,Siddique MA,Haque MA .2024 .Comparative invitro evaluation of ebastine tablets (10 mg) available in bangladesh. Bangladesh Journal of Medical Science, 23(1) : 70673-53.
Etman MA,Gamal M,Nada AH .2014 .Formulation of desloratadine oral disintegrating tablets. , 10(11) : 054-61.
Zhao H,Yu Y,Ni N,Zhao L,Lin X,Wang Y .2021 .A new parameter for characterization of tablet friability based on a systematical study of five excipients. , 611 : 121339.
Parmar KA,Tandel FB,Rabari DJRJoP .2015 .Analytical method development and validation of desloratadine tablet. , 00109(6) : 0974-360X.
Dhakal B,Thakur JK,Mahato RK,Rawat I,Rabin D,Chhetri RR .2022 .1):9618344. The Scientific World Journal, : .
Du J,Hoag SWJDd .2015 .pharmacy i. Characterization of excipient and tableting factors that influence folic acid dissolution, friability, and breaking strength of oil-and water-soluble multivitamin with minerals tablets. , 02(10) : 1137-47.
Domokos A,Nagy B,Szilagyi B,Marosi G,Nagy ZK .2021 .Integrated continuous pharmaceutical technologies-a review. Organic Process Research & Development, 25(4) : 721-39.
Brown WE .2005 .Compendial Requirements of Dissolution Testing-European Pharmacopoeia, Japanese Pharmacopoeia, United States Pharmacopeia. , : 87-98.
Akgeyik E,KAYNAK M,Çelebier M,ALTINÖZ S,Şahin SJDT .2016 .Evaluation of pharmaceutical quality of conventional dosage forms containing paracetamol and caffeine available in the Turkish drug market. DOI: 10.14227/dt230216p36, 23(2) : .
Dash S,Murthy PN,Nath L,Chowdhury P .2010 .Kinetic modeling on drug release from controlled drug delivery systems. Acta Pol Pharm, 20524422(3) : 217-23.
Gouda R,Baishya H .2017 .Application of mathematical models in drug release kinetics of carbidopa and levodopa ER tablets. J Dev Drugs, 10(02) : 1000171-6631.
0

Citations

0

Downloads

6

Views